1217 Article Views
Publication Date: 29 Sep 2011
Journal: Biomarker Insights
doi: 10.4137/BMI.S8247
A pivotal role in guiding mesenchymal stem cell (MSC) differentiation has recently been attributed to the primary cilium. This solitary, non-motile microtubule-based organelle emerging from the cell surface acts as a sensorial membrane structure reflecting developmental and adaptive processes associated with pathologies including human cystic kidney disease, skeletal malformations, obesity and cancer. Given that the intrinsic hypoxic adaptation of MSC remains poorly understood within ischemic tissues or hypoxic tumours, we questioned whether the hypoxia inducible factor-1 (HIF-1) might be a downstream effector regulating cilium maintenance. We show that murine bone marrow-derived MSC cultured under hypoxic conditions (1.2% O2) lose their primary cilia in a time-dependent manner. Gene silencing of HIF-1 prevented cilia loss in hypoxic cultures, and generation of MSC expressing a constitutively active HIF-1 (MSC-HIF) was found to decrease primary cilium formation. A Wnt pathway-related gene expression array was also performed on MSC-HIF and indicated that the secreted Frizzled-related proteins (sFRP)-1, -3 and -4 were down-regulated, while sFRP-2 was up-regulated. Overexpression of recombinant sFRP-2 or gene silencing of sFRP-1, -3 and -4 in MSC led to primary cilium disruption. These results indicate a molecular signalling mechanism for the hypoxic disruption of the primary cilium in MSC involving an HIF-1/sFRP axis. This mechanism contributes to our understanding of the adaptive processes possibly involved in the oncogenic transformation and tumour-supporting potential of MSC. Our current observations also open up the possibility for the primary cilia to serve as a biomarker in MSC adaptation to low oxygen tension within (patho)physiological microenvironments.
Discussion
No comments yet...Be the first to comment.
The editorial staff of Biomarkers in Cancer are very efficient and helpful. I am happy to work with them. I look forward to reviewing future manuscripts.Dr Xi Liu (National Cancer Institute, National Institutes of Health, Bethesda, MD, USA ) What Your Colleagues Say
Copyright © 2012 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)
FacebookGoogle+Twitter
PinterestTumblrYouTube